Tumor Genotyping and Clinical Decision-Making

The National Cancerology Institute in Mexico strengthens its scientific capabilities in tumor genotyping, which allows for the identification of specific genetic alterations in different types of cancer. This advance is based on the operation of the Genotyping, Digital PCR, Genomics, and Bioinformatics Unit (UniGPGBio), an infrastructure aimed at consolidating a precision medicine model centered on the patient. During the institute's Annual Multidisciplinary Meeting, significant advances in the technological, methodological, and operational implementation of this unit were presented. This project is part of an institutional initiative to strengthen personalized cancer care, integrating genomic and bioinformatics tools into daily clinical practice. The institute's director general emphasized that tumor genotyping is an essential tool for identifying specific genetic alterations, allowing molecular information to be transformed into evidence-based therapeutic decisions. He explained that this type of analysis makes it possible to detect actionable mutations, i.e., genetic changes that guide the selection of targeted therapies and optimize treatment protocols. The integration of advanced genomic technologies, including next-generation sequencing (NGS) platforms, the standardization of real-time PCR techniques, and the strengthening of bioinformatics processes, has enabled the achievement of international standards in the molecular analysis of cancer. He indicated that the first NGS sequencing trials in solid tumors already meet clinical and molecular quality parameters, allowing for the issuance of reliable genomic reports that can be integrated into medical decision-making. Another relevant aspect highlighted by the specialist is the importance of generating genomic evidence specific to the Mexican population, as the epidemiological characteristics of cancer can vary by region. In this context, having genetic information generated in the country allows for the development of therapeutic alternatives more aligned with the national clinical reality. The development of this unit has been made possible through the articulated collaboration between clinical, scientific, and academic areas.